Boston Scientific generated $20.6B in trailing twelve-month revenue, up 0.2% year-over-year. Net income was $3.6B with a 17.26% net margin. Gross margin stands at 69.16% and operating margin at 18.4%. Diluted EPS is $2.39, which grew 0.7% year-over-year. Based on the Q1 2026 filing.